Form 4: Checkpoint Therapeutics CEO Receives 1.5 Million Restricted Shares

Checkpoint Therapeutics CEO, James F. Oliviero III, was granted 1.5 million restricted shares of common stock, vesting over three years.

Summary

• James F. Oliviero III, CEO, President, and Director of Checkpoint Therapeutics, Inc., received 1,500,000 shares of restricted common stock on January 30, 2025.
• These shares were granted at a price of $0.
• The restricted shares will vest in three equal installments: one-third on January 30, 2026, one-third on January 30, 2027, and the final third on January 30, 2028.
• Following this transaction, Mr. Oliviero beneficially owns a total of 3,794,583 shares of common stock, including previously granted restricted shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of restricted stock aligns the CEO's interests with the long-term performance of the company.
• The vesting schedule encourages continued leadership and commitment from the CEO.

Risks

• The vesting of the shares is contingent on the CEO's continued employment with the company.
• The value of the shares is subject to market fluctuations and the company's performance.

Future Outlook

The CEO's long-term compensation is tied to the company's performance through the vesting of the restricted stock.

Industry Context

Stock grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock grants are a standard practice for executive compensation in the biotech industry, often used to attract and retain top talent.
• Vesting schedules, like the three-year plan here, are typical to ensure long-term commitment from executives.
• Companies like Amgen, Gilead, and Regeneron also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the stock grant positively as it incentivizes the CEO to improve company performance.
• Employees may see this as a sign of stability and commitment from the leadership.

Key Dates

Keywords

restricted stock, stock grant, CEO, Checkpoint Therapeutics, equity compensation, insider trading, beneficial ownership